[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"penetrating-aortic-ulcer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:penetrating-aortic-ulcer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,64,90,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100212530","evaluation-of-the-cook-custom-aortic-endograft-the-zenith-t-branch-endovascular-graft-and-surgeon-modified-endograft-in-treating-aortic-pathologies-100212530",false,"NCT02043691","Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies","Evaluation of All-Cause Mortality and Pulmonary Morbidity in Treating Juxtarenal, Suprarenal, Thoracoabdominal, and Aortic Arch Pathologies Using Cook Custom Aortic Endografts, the Zenith t-Branch Endovascular Graft, and the Surgeon-Modified Endograft","Inclusion Criteria:\n\n* Juxtarenal, suprarenal, and thoracoabdominal aortic pathology as follows in hemodynamically stable patients:\n\n  1. Intact or contained ruptured aortic or aortoiliac aneurysms (atherosclerotic\u002Fdegenerative or saccular) involving or in close approximation to the visceral segment of the aorta.\n\n     1. Diameter \\> 5.5 cm if asymptomatic, or 5.0 cm with enlargement of \\> 0.5 cm in 6 months.\n     2. History of growth \\> 0.5 cm per year\n     3. Any size if ruptured or symptomatic\n  2. Penetrating aortic ulcer (PAU)\n\n     1. \\> 2.0 cm in depth\n     2. Any size if contained ruptured or symptomatic\n  3. Subacute (\\>14 days) or chronic (\\>20 days) aortic dissection with aneurysmal degeneration with at least one of the following:\n\n     1. Total aortic diameter \\> 5.5 cm if asymptomatic\n     2. Total aortic diameter \\> 4.5 cm if symptomatic\n     3. Total aortic diameter \\> 5.0 cm and history of growth \\> 0.5 cm in 6 months\n* Aortic Arch pathology:\n\n  1. Aneurysm, Ascending thoracic aortic pseudoaneurysm, Type A thoracic aortic dissection, Retrograde type A thoracic aortic dissection between the Sinus of Valsalva and the innominate artery orifice (without involvement of the Aortic Valve), or Ascending penetrating aortic ulcer with and without intramural hematoma\n  2. Suitable iliac artery and brachial artery access\n  3. Absence of severe landing zone (\\> 90 degree) angulation that would preclude necessary device delivery\u002Fseal\u002Ffixation.\n  4. Suitable iliac artery access to accommodate device delivery system.\n  5. Target arteries for arch branches:\n\n     1. \\\u003C 24 mm diameter\n     2. Adequate landing zone length to obtain proximal and distal seal.\n     3. Free from dissection precluding adequate seal in distal landing zone of branch stent and severe tortuosity\u002Fthrombus\u002Fcalcification.\n* Aortic Arch Aneurysm\n\n  1. Proximal aortic fixation zone:\n\n     1. Native aorta or surgical graft\n     2. Diameter: 20 - 42 mm\n  2. Proximal neck length \\> 20 mm\n  3. Must occur distal to coronary arteries and any coronary artery bypass grafts that are considered patent and necessary for proper cardiac perfusion.\n  4. Distal aortic fixation zone:\n\n     1. Native aorta or surgical graft\n     2. Diameter: 20 - 44 mm\n  5. Distal neck length \\> 20 mm. However, if dissection, distal graft may land in dissected aorta.\n  6. Supra-aortic trunk (brachiocephalic) vessels (Any combination of arteries may be used for repair) A. Innominate artery\n\n     1. Native vessel or surgical graft\n     2. Diameter: 8 - 22 mm\n     3. Length of sealing zone \\> 10 mm\n     4. Acceptable tortuosity B. Left (or right) common carotid artery\n\n     \u003C!-- -->\n\n     1. Native vessel or surgical graft\n     2. Diameter 5 - 20 mm\n     3. Length of sealing zone \\> 10 mm C. Left (or right) subclavian artery\n\n     \u003C!-- -->\n\n     1. Native vessel or surgical graft\n     2. Diameter 5 - 20 mm\n     3. Length of sealing zone \\> 10 mm\n* Aortic Dissection\n\n  1. Access into the true lumen from the groin and at least one supra-aortic trunk vessel.\n  2. Seal zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent-graft would be anticipated to seal off the dissection lumen.\n  3. Seal zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen or surgically created.\n  4. True lumen size large enough to deploy the device and still gain access into the target branch.\n\nGeneral Exclusion Criteria:\n\n* Less than 18 years of age\n* Life expectancy less than 12 months based on the surgeon's assessment\n* Pregnant or breastfeeding or planning on becoming pregnant within 60 months\n* Inability or refusal to give informed consent\n* Unwilling or unable to comply with the follow-up schedule\n* Less than 30 days beyond primary endpoint for other investigative drug or device study\n\nMedical Exclusion Criteria:\n\n* Known allergy to the device components (i.e. stainless steel, polyester, solder, gold, or nitinol)\n* History of anaphylactic reaction to contrast material that cannot be adequately premedicated\n* Systemic or local infection that may increase the risk of endovascular graft infection.\n* Baseline eGFR \\\u003C 30 mL\u002Fmin (calculated by the Modification of Diet in Renal Disease formula) and not on hemo- or peritoneal dialysis. If the patient is currently on dialysis, or is currently planning on initiating dialysis, then they may undergo repair.\n* Body habitus that would inhibit X-ray visualization of the aorta.\n* Major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair.\n* Unstable angina, defined as a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina.\n* Irreversible coagulopathy\n\nAnatomical Exclusion Criteria:\n\n* Aortic transection due to acute trauma.\n* Infectious (\"mycotic\") etiology of the aortic disease.\n* Significant occlusive disease or tortuosity precluding delivery of the device components.\n* Juxtarenal, Suprarenal, and Thoracoabdominal:\n* Proximal Landing zone \\\u003C 20 mm in length. The proximal landing zone can be within zones 2 through 8, with least 20 mm of proximal seal and fixation in aorta or Dacron.\n* Proximal neck, defined as the thoracic aorta distal to the native left carotid artery, measured outer wall to outer wall on a sectional image (CT) \\> 41 mm in diameter or \\\u003C 18 mm in diameter\n* Distal landing zone \\\u003C 20 mm in length if the landing zone is in the aorta, or \\\u003C 20 mm if the landing zone is in the iliac arteries or in Dacron (in the event the patient has had a previous or concomitant aortic or aorto-iliac reconstruction).\n* Untreatable branch vessel stenosis.\n* Anatomy that would not allow maintenance of at least one patent hypogastric artery.\n* Signs that the inferior mesenteric artery (IMA) is indispensable (i.e. angiographic visualization or a large IMA, filling of superior mesenteric artery (SMA) via collaterals, stenosis of celiac or SMA or oblique views) and the indispensable IMA is not amenable to treatment with a graft branch or fenestration.\n* Branching, duplication, aneurysm or untreatable stenosis of the celiac, SMA or renal arteries that would preclude implantation of the investigational devices.\n* Aortic arch:\n* Proximal neck \\> 44 mm or \\\u003C 28 mm in diameter\n* Inadequate landing zone to allow adequate distal seal of exclusion of false lumen perfusion in dissection.\n* Untreatable branch vessel stenosis.\n* Significant occlusive disease, tortuosity, or calcification that would prevent endovascular access.\n* Patients qualifying for an industry-sponsored study allowing for a similar repair will be enrolled in the industry-sponsored study.","ALL","18 Years",{"count":19,"type":20},410,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a single-center study to evaluate the safety and effectiveness of three investigational devices, the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and the Surgeon-Modified Endografts in the treatment of Juxtarenal, Suprarenal, Thoracoabdominal, and Aortic Arch pathologies involving the at least one brachiocephalic artery or visceral vessels.\n\nThe three investigational devices offer an endovascular approach to treat complex aortic pathologies that cannot be treated with commercially available devices. This customized, endovascular approach has the potential to decrease hospital length of stay, pulmonary complications, and in-hospital mortality.",[26,27,28,29,30,31],"Juxtarenal Aortic Aneurysm","Suprarenal Aortic Aneurysm","Thoracoabdominal Aortic Aneurysm","Penetrating Aortic Ulcer","Aortic Arch Aneurysm","Aortic Dissection",[33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50],"Endovascular","Aortic","Aneurysm","Thoracoabdominal","Juxtarenal","Suprarenal","Endograft","Fenestrated","Branched","Complex","Abdominal","Thoracic","Stent","Stentgraft","Arch","Ascending","Dissection","Descending","RECRUITING","2026-01-02",{"date":54,"type":55},"2026-01-06","ACTUAL",{"date":57,"type":55},"2014-06",{"date":59,"type":20},"2027-10",{"name":61,"class":62},"University of Alabama at Birmingham","OTHER",1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100398727","nexus-aortic-arch-clinical-study-to-evaluate-safety-and-effectiveness-100398727","NCT04471909","NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness","A Multi-arm, Multi-Center, Non-Randomized, Prospective, Clinical Study to Evaluate the Safety and Effectiveness of the NEXUS Aortic Arch Stent Graft System in Treating Thoracic Aortic Lesions Involving the Aortic Arch","TRIOMPHE","Inclusion Criteria:\n\n1. Male and female age ≥ 18.\n2. Proximal\u002Fascending native or previously implanted surgical graft landing zone of appropriate length\n3. Proximal\u002Fascending native or previously implanted surgical graft landing zone of appropriate diameter\n4. Distal\u002Fdescending native landing zone of appropriate length\n5. Distal\u002Fdescending native landing zone of appropriate diameter\n6. Brachiocephalic trunk native landing zone of appropriate length\n7. Brachiocephalic trunk native landing zone of appropriate diameter\n8. Appropriate take off angle between the Brachiocephalic Artery and the Aortic Arch perpendicular\n9. Appropriate aortic arch perpendicular diameter\n10. Chronic dissection with at least one of the following conditions:\n\n    1. An aortic aneurysm with a maximum diameter ≥ 55 mm\n    2. Rapidly expanding false lumen (growth of \\> 0.5 cm\u002F6 months)\n    3. Compressed true lumen associated with end organ malperfusion\n    4. Symptomatic\n11. Aneurysm with at least one of the following conditions:\n\n    1. Dilatation of the aortic arch larger than 5 cm in diameter for subject with fusiform aneurysm\n    2. Dilatation of the aortic arch is 1.5 times the normal diameter for subjects ascending or descending\n    3. Dilation of the aortic arch larger than 2.5 cm for subject with saccular aneurysm\n    4. Symptomatic aneurysm of the aortic arch\n    5. Aortic diameter growth rate \\> 5mm per 6 months\n    6. Postoperative pseudoaneurysm expanding from anastomotic suture lines\n12. Penetrating aortic ulcer with at least one of the following:\n\n    1. Symptomatic\n    2. Ulcer demonstrates expansion\n13. Intramural hematoma with at least one of the following:\n\n    1. Symptomatic (persistent pain)\n    2. Transverse or longitudinal expansion on serial imaging\n14. In the event of a lesion in the ascending aortic, the proximal\u002Fascending native or previously implanted surgical graft the landing zone must be appropriate\n15. Femoral \u002F iliac artery diameter as documented by CTA or MRA that allows endovascular access to the diseased site with a 20 Fr. delivery catheter.\n16. Access vessels morphology suitable for endovascular repair in terms of tortuosity, calcification and angulation, documented by CTA\u002FMRA.\n17. Brachial\u002FAxial Artery diameter that allows endovascular access suitable for 7 Fr.\n18. Subject is considered an appropriate candidate for an elective surgery.\n19. Subject is considered to be at high risk for open repair, as determined by the investigator.\n20. Access vessels, iliac\u002Ffemoral \\& brachial\u002Faxillary compatible with vascular access techniques (femoral cutdown or percutaneous), devices, and \u002For accessories.\n21. Subject is willing and able to comply with procedures specified in the protocol and is able to return for follow-up visits as specified by the protocol.\n\nExclusion Criteria:\n\n1. Acute dissection\n2. Lesions that can be safely treated with TEVAR landing in zone 2 (with or w\u002Fo LSA vascularization)\n3. Required emergent treatment, e.g., trauma, rupture\n4. Acute vascular injury of the aorta due to trauma\n5. Aortic rupture or unstable aneurysm\n6. Received a previous stent or stent graft in the treated area (including planned landing area)\n7. Required surgical or endovascular treatment of an infra-renal aneurysm at time of implantation\n8. Planned major surgical or interventional procedure at time of screening, to be performed after the NEXUS™ implantation.\n9. Any major surgical or interventional procedure 6 weeks before the NEXUS™ implantation, exclusive of planned procedures that are needed for the safe and effective placement of the stent graft (e.g. supra-aortic bypass).\n10. Subject has had a myocardial infarction (MI) or cerebral vascular accident (CVA) within 90 days prior to the planned implantation\n11. Subjects with severe aortic valvular insufficiency as determined by echocardiography\n12. Mechanical valve that preclude safe delivery of NEXUS™\n13. Known Connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndromes)\n14. Subject has an active systemic infection at the time of the procedure documented by pain, fever, drainage, positive culture\n15. Pregnant\n16. Life expectancy of less than 2 years\n17. Unsuitable vascular anatomy\n18. Subject who have a previously implanted surgical wrap of the ascending aorta\n19. Any medical condition that, according to the investigator's decision, might expose the subject to increased risk by the investigational device or procedure.\n20. An aneurysm that is mycotic, inflammatory or suspected to be infected.\n21. Subject with hostile groins\u002Faxilla (scarring, obesity, or previous failed puncture) unless conduit are used.\n22. Subjects with severe atherosclerosis, severe calcification or extensive intraluminal thrombus of the aorta or in the brachiocephalic trunk\n23. Subject is suffering from unstable angina or NYHA classification III and IV.\n24. Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to pre-treatment.\n25. Subject with a contraindication to undergo angiography\n26. Subject with known sensitivities or allergies to the device materials (including Nitinol \\[NiTi\\], polyester fabric \\[PET\\], tantalum \\[TA\\])\n27. Clinical conditions that severely inhibit x-ray visualization of the Aorta.\n28. Subject has history of bleeding diathesis or coagulopathy that may limit the use of dual antiplatelet or anticoagulant therapy by the decision of the investigator\n29. Acute renal failure; chronic renal failure (excluding dialysis); Creatinine \\> 2.00 mg\u002Fdl\n30. Any other medical, social, or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, or the procedures and evaluations pre- and post- treatment.\n31. Active participation in another clinical study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints in this study, or subject is planning to participate in such study prior to the completion of this study.",{"count":73,"type":20},110,[23],"Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.",[31,77,78,29],"Aortic Aneurysm","Intramural Hematoma","2025-10-16",{"date":81,"type":55},"2025-10-20",{"date":83,"type":55},"2020-10-20",{"date":85,"type":20},"2029-10",{"name":87,"class":88},"Endospan Ltd.","INDUSTRY",32,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100556106","concave-supra-arch-branched-stent-graft-system-for-endovascular-treatment-of-aortic-arch-diseases-100556106","NCT06520774","Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases","A Prospective, Multicenter, Single-Group Target-Value Clinical Trial: Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases","Inclusion Criteria:\n\n1. Patients who are aged 18 to 80 years inclusive；\n2. Patients diagnosed with aortic arch aneurysms or penetrating ulcers that require intervention, and for whom the proximal end of the stent needs to be anchored in the Z0 zone;\n3. Anatomical criteria, including:\n\n   1. Ascending aorta length is greater than or equal to 50 mm (distance from aortic sinus to anterior edge of innominate artery);\n   2. The diameter range of the anchoring area at the proximal end of the main body is between 25-45 mm and the length is greater than or equal to 30 mm;\n   3. The diameter of the anchored area of supra-arch branch vessels (innominate artery, left common carotid artery, left subclavian artery) is between 5-18 mm, distal anchorage length is greater than or equal to 15 mm;\n   4. Distance between the anterior edge of the innominate artery to the posterior edge of the left subclavian artery is less than or equal to 80 mm;\n   5. Have a suitable iliac, femoral, and superior arch arterial access;\n4. At least two researchers should assess that the subject is a high-risk patient for surgical treatment or has significant contraindications to surgery. It is recommended to refer to the following criteria: a score of ≥6 in the European System for Cardiac Operative Risk Evaluation (EuroSCORE) scoring system.;\n5. Patients who understand the purpose of the study, volunteer to participate and sign the informed consent form, and are willing to complete follow-up visits as required by the protocol.\n\nExclusion Criteria:\n\n1. Patients either with ruptured or infected aneurysms;\n2. Patients with aortic dissection;\n3. Patients with general or local infections that may increase the risk of endovascular graft infection;\n4. Patients with severe stenosis, calcification, or mural thrombus in the stent anchoring area, which is likely to impede stent-graft adherence or affect stent patency;\n5. Previous endovascular intervention involving the aortic arch;\n6. Underwent open or endovascular surgery for abdominal aorta within the past 3 months;\n7. Patients with a history of stroke within the past 3 months (excluding TIA);\n8. Patients with aneurysms involving the distal descending aorta and requiring reconstruction of important visceral branch vessels within the abdomen;\n9. Patients with a history of myocardial infarction within the past 3 months;\n10. Patients with congestive heart failure - NYHA Class IV;\n11. Patients allergic to contrast agents, stent and delivery system materials (such as nitinol, polyester, PTFE, nylon polymer materials);\n12. Patients with contraindications to anticoagulant or antiplatelet drugs;\n13. Patients unable to tolerate general anesthesia;\n14. Patients with abnormal liver and kidney function before surgery (ALT or AST more than 5 times the upper limit of normal; serum creatinine (Cr) \\>150umol\u002FL);\n15. Patients with connective tissue diseases, such as Marfan syndrome, Ehlers-Danlos syndrome, or Behcet's disease;\n16. Patients with arteritis;\n17. Patients with a life expectancy of less than 1 year;\n18. Women who are planning to conceive, pregnant or breastfeeding;\n19. Patients deemed by the investigator as unsuitable for endovascular treatment;\n20. Patients who have participated in other clinical studies and have not withdrawn or been excluded within the 3 months prior to the screening period of this study.","80 Years",{"count":99,"type":20},103,[23],"The objective of the study is to evaluate the safety and efficacy of the Lifetech Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases",[30,29],[104,105,106],"Lifetech","Concave Supra-arch Branched Stent-Graft System","Endovascular Treatment","2025-07-25",{"date":109,"type":55},"2025-07-28",{"date":111,"type":55},"2024-05-30",{"date":113,"type":20},"2031-06-30",{"name":115,"class":88},"Lifetech Scientific (Shenzhen) Co., Ltd.",17,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":63},"100506424","cratos---evaluation-of-cratos-branch-stent-graft-system-in-treatment-of-descending-aorta-lesions-100506424","NCT05874206","CRATOS - Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions","Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions","Inclusion Criteria:\n\n1. Presence of thoracic aortic pathology (Dissection, including IMH and ULP; and PAU) deemed to warrant surgical repair which requires proximal graft placement in Zone 2\n2. Age ≥18 years at time of informed consent signature\n3. Informed Consent Form (ICF) is signed by Subject or legal representative\n4. Must have appropriate proximal aortic landing zone, defined as:\n\n   * Landing zone inner diameters between 23-41 mm\n   * The length of landing zone ≥15mm\n   * Landing without heavily calcified or heavily thrombosed\n   * Dissection Patients: Primary entry tear must be distal to LSA, and proximal extent of the proximal landing zone must not be dissected.\n   * For patients with prior replacement of the ascending aorta and\u002For aortic arch by a surgical graft, there must be at least 2 cm of landing zone proximal to the most distal anastomosis site.\n5. Must have appropriate LSA landing zone, defined as:\n\n   * Inner diameters of LSA 5-14 mm\n   * Minimum length of Left subclavian artery is 25 mm\n   * Target branch vessel landing zone must be in native aorta that cannot be severely tortuous , aneurysmal, dissected, heavily calcified, or heavily thrombosed.\n6. Must have appropriate distal aortic landing zone, defined as:\n\n   * Aortic inner diameters between 18-44 mm\n   * Landing zone cannot be heavily calcified, or heavily thrombosed.\n   * For isolated PAU, outer curvature length must be ≥ 2cm proximal to the celiac artery\n   * Landing zone in native aorta\n\nExclusion Criteria:\n\n1. Concomitant disease of the ascending aorta or aneurysm of the abdominal aorta requiring repair\n2. Previous endovascular repair of the ascending aorta\n3. Infected aorta, active systemic infection\n4. Surgery within 30 days prior to enrolment with the exception of placement of vascular conduit for access .\n5. Life expectancy \\\u003C1 years\n6. Myocardial infarction within 6 weeks prior to treatment\n7. Stroke within 6 weeks prior to treatment.\n8. Pregnant or breastfeeding female\n9. Patient has an active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication) that may place the patient at increased risk of endovascular infection.\n10. Degenerative connective tissue disease, e.g., Marfan's or Ehlers-Danlos Syndrome\n11. Participation in another drug or medical device study within one year of study enrolment\n12. Known history of drug abuse within one year of treatment\n13. Tortuous or stenotic iliac and\u002For femoral arteries preventing introducer sheath insertion and the inability to use a conduit for vascular access\n14. Planned coverage of celiac artery\n15. Allergic to contrast agents, anaesthetics and delivery materials\n16. Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin\n17. Patient with a history of a hypercoagulability disorder and\u002For is currently in a hypercoagulability state\n18. Persistent refractory shock (systolic blood pressure \\\u003C90 mm Hg)\n19. Renal failure defined as patients with an estimated Glomerular Filtration Rate (eGFR) \\\u003C30 (ml\u002Fmin\u002F1.73 m2) or currently requiring dialysis\n20. Contraindications to antiplatelet drugs and anticoagulants\n21. Investigator judged that not suitable for interventional treatment.",true,{"count":126,"type":20},130,[23],"The goal of this prospective, interventional, multicentre, single-arm performance objective study is to evaluate efficacy and safety of Cratos™ Branch Stent Graft System in treatment of lesions (dissection, IMH and PAU in descending aorta. The main question\\[s\\] it aims to answer are:\n\n* 30-day all-cause Mortality rate\n* Composite of the following events from the time of enrolment through 12-month:\n\n  * Device Technical Success\n  * Absence of: Aortic rupture, Lesion-related mortality, Disabling Stroke, Permanent paraplegia, Permanent paraparesis, New onset renal failure requiring permanent dialysis, Additional unanticipated post-procedural surgical or interventional procedure related to the device, procedure, or withdrawal of the device system\n\nParticipants will come for hospital office visits 1, 6, 12, 24-, 36-, 48- and 60-months post-procedure for the following, but not limited to assessments:\n\n* Physical examination\n* Modified Rankin scale\n* Tarlov scoring scale\n* CTA",[130,78,29],"Aortic Dissection Type B","2025-02-24",{"date":133,"type":55},"2025-02-26",{"date":135,"type":55},"2024-03-08",{"date":137,"type":20},"2031-12",{"name":139,"class":88},"Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd"]